Appointment of Berthold Hackl and Dr. Eduard Ayuso to Board of Directors

Press Release:
The two industry experts are joining PlasmidFactory’s board to further support the strategic development and positioning of the company; their vast industrial and scientific insight will contribute significantly to PlasmidFactory’s growth acceleration.
“We are pleased to welcome Berthold and Eduard to the PlasmidFactory Board," said Dr. Martin Schleef, CEO of PlasmidFactory. "Berthold’s extensive business and transaction experience, and Eduard’s deep scientific knowledge in life science will be invaluable to PlasmidFactory as we pursue our growth and expansion in the continuously evolving mRNA and C&GT industries where plasmid and minicircle DNA manufacturing play a key role."

PlasmidFactory opened a new HQ (High Quality) production facility that is generating high quality, cutting-edge plasmids as well as minicircles in large scale, and since partnering with global healthcare-focused private equity firm ARCHIMED in September 2022, has been working actively to build a GMP (Good Manufacturing Practices)-compliant facility to continue meeting the needs of the client base.
This carefully planned capacity expansion will allow PlasmidFactory to further establish and leverage its unrivaled reputation as provider of exceptionally high quality and reliable starting materials for gene and cell therapy as well as RNA vaccines.
Both industry experts were recruited through ARCHIMED’s MedTalents^®, a global network of associated senior healthcare executives who identify, facilitate and advise on deals and counsel portfolio companies.
Berthold Hackl is a successful executive, advisor and board member in the life sciences across VC, PE and public environments and at various life sciences related companies. He brings with him over thirty years of industrial experience in Europe and the US in the areas of equity raising, buy-and-build, exits and the development of new markets.